A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

• Participants must have a histologically confirmed diagnosis of locally advanced, unresectable (not suitable for curative surgery or radiotherapy) or metastatic renal cell carcinoma (RCC).
• Participants must have clear RCC (ccRCC) or non-clear RCC (nccRCC) that can be included in Part 1. Note: Part 2 can only include participants with ccRCC.
• Participants can be classified into the risk categories of 'favorable', 'intermediate', or 'unfavorable'.
• Participants must not have received prior systemic therapy for metastatic RCC, with the following exceptions:
i) A prior adjuvant or neoadjuvant therapy for completely resectable RCC is allowed if this therapy does not contain any agents targeting vascular endothelial growth factors (VEGF) or VEGF receptors, and if a relapse occurs at least 6 months after the last dose of the adjuvant or neoadjuvant therapy.
ii) For participants in Part 1A: A prior systemic therapy in the metastatic setting is allowed if the participant has not received therapy targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) (e.g., Ipilimumab).
iii) For participants in Part 1B: A prior systemic therapy in the metastatic setting is allowed if the participant has not received prior treatment with Cabozantinib.

• Participants must have measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) V1.1. • Other protocol-defined inclusion/exclusion criteria apply.

(BASEC)

Participants must not have untreated known CNS metastases.
Participants must not have received systemic treatment with corticosteroids (> daily 10 mg prednisone equivalent) or other immunosuppressive medications within 14 days prior to Cycle 1 Day 1 (C1D1).
• Participants must not have a history of interstitial lung disease or pneumonitis.
• Participants must not have uncontrolled pleural or pericardial effusion requiring repeated therapeutic drainage procedures.
• Participants must not have significant cardiovascular diseases such as myocardial infarction, unstable angina, arterial thrombosis, cerebrovascular accidents, or uncontrolled hypertension (≥ 150 systolic, ≥ 90 diastolic mm Hg) despite optimal medical treatment.
• Participants must not have urine protein ≥ 2+ and 24-hour urine protein ≥ 1 g at baseline.
• Participants must not have evidence of significant coagulation disorders.
• Participants must not have a history of deep vein thrombosis, pulmonary embolism, or other significant thromboembolic events within 6 months prior to C1D1.
• Participants must not have a history of abdominal fistula or gastrointestinal (GI) perforation within 6 months.
• Participants must not have undergone major surgery or experienced trauma within 28 days prior to C1D1.
• Other protocol-defined inclusion/exclusion criteria apply.

(BASEC)